Experts Discuss the Unique Management of Advanced Hepatocellular Carcinoma in the Era of COVID-19

Experts Discuss the Unique Management of Advanced Hepatocellular Carcinoma in the Era of COVID-19

COVID-19 has had a national and global impact on the way cancer patients are treated. Hepatocellular cancer (HCC) patients have unique treatment patterns making managing these patients amidst the pandemic especially challenging. Hear Thomas Abrams, MD and Richard Finn, MD discuss topics such as TACE, I-O, TKIs, orals vs infusions, telemedicine, guidelines, and more as it relates to treating HCC patients today while COVID-19 remains a threat.

Date Recorded: 7:30PM ET on May 19th

Watch video now

Panelists:


 Thomas A. Abrams, MD
Thomas A. Abrams, MD
Assistant Professor of Medicine
Harvard Medical School
Richard S. Finn, MD
Richard S. Finn, MD
Professor of Medicine
Geffen School of Medicine at UCLA

This webinar will be recorded and archived for future use.